Nanobiotix Reports 79% Locoregional Control in Recurrent Lung Cancer Trial
Nanobiotix's updated Phase 1 data for JNJ-1900 (NBTXR3) in inoperable, locoregionally recurrent NSCLC show no dose-limiting toxicities and a feasible intratumoral injection, with one-year results of 79% locoregional control, 61% LPFS, and 70% OS achieved at a lower re-irradiation dose. The findings reinforce the hafnium oxide nanoparticle–based radiosensitizer's potential to enable safe retreatment and spur further enrollment in dose-escalation and expansion cohorts.
Health · 6 sources · Sep 14, 2026Read itThe journal
Open the journal →The conversation starts in the journal — be the first to post.
About Nanobiotix
Nanobiotix is a biotechnology company that uses nanomedicine to develop new radiotherapy techniques for cancer patients. The company is headquartered in Paris, with additional corporate offices in New York and Massachusetts.
Everything about Nanobiotix →- Country
- France
- Headquarters
- Paris
- Inception
- 2003
- Website
- http://nanobiotix.com/